SERINA THERAPEUTICS INC
Huntsville, AL · CIK 0001558525 · Biotech · Public
Polymer-based delivery systems for small molecule therapeutics
serinatherapeutics.com →- Grants
- $4.3M
- 5 awards
- Sector median: 1
- Raised
- $34M
- 9 Form D · Mar 2023
- 42 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 16 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,000,000 | |
| Private capital raised | Form D · SEC | $2,000,000 | |
| Private capital raised | Form D · SEC | $11,150,080 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $4,055,900 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke | $385,923 | |
| Federal grant | Department of Health and Human Services · Phase I · Metabolically Reprogrammed Mesenchymal Stem Cells for Treating Osteoporosis | $224,973 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Single Dose Long-Acting Non-Addictive Polymer Conjugate Formulation of Buprenorphine that Provides Immediate and Prolonged Analgesia for Post-Operative Pain | $1,658,634 | |
| Federal grant | Department of Health and Human Services · Phase I · A single dose long-acting non-addictive polymer conjugate formulation of buprenorphine that provides immediate and prolonged analgesia for post-operative pain | $1,658,634 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $3,650,000 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease | $340,956 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1756 | LAMNOTHERAPEUTICS, INC. | — | — |
| 1757 | REACTIVE BIOSCIENCES INC | — | $43M |
| 1758 | Aerpio Therapeutics LLC | — | $45M |
| 1759 | SERINA THERAPEUTICS INC | — | $34M |
| 1760 | Iterative Therapeutics Inc. | — | — |
| 1761 | Rhodium Scientific, LLC | — | — |
| 1762 | Klogene Therapeutics, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Greg Bailey, M.D.Director
- Michael BentleyDirector · Executive Officer
- Barbara FiskDirector
- J HarrisDirector · Executive Officer
- James Hudson, Jr.Director
- Steve LedgerDirector
- Miguel LoyaDirector
- Lonnie McMillianDirector
- Randall MoreadithDirector · Executive Officer
- Brendan RaeExecutive Officer
- Tacey ViegasExecutive Officer
Patents
- Polyoxazoline-lipid Conjugates And Lipid Nanoparticles And Pharmaceutical Compositions Including Samegranted
- Targeting Of Antigen-presenting Cells By Nanoparticles Containing Polyoxazoline-lipid Conjugatesapplication
- Subcutaneous Delivery Of Polymer Conjugates Of Therapeutic Agentsgranted
- Multifunctional Forms Of Polyoxazoline Copolymers And Drug Compositions Comprising The Samegranted
- Cleavable Conjugates of Catechol Compounds and Water-Soluble Polymers and Methods of Treatment Using the Samegranted
- Subcutaneous Delivery Of Polymer Conjugates Of Therapeutics Agentsgranted
- Subcutaneous Delivery Of Poly(oxazoline) Polymer Conjugatesgranted
- Multifunctional Forms Of Polyoxazoline Copolymers And Drug Compositions Comprising The Samegranted
- Polyoxazoline Anitbody Drug Conjugatesgranted
- Activated Polyoxazolines And Conjugates And Compositions Comprising The Samegranted
- Subcutaneous Delivery Of Polymer Conjugates Of Therapeutic Agentsgranted
- Subcutaneous Delivery of Poly(oxazoline) Polymer Conjugatesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.